Best Lymphoma Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

No single hospital is automatically best — and for lymphoma, the most important factors are whether the team is led by a haemato-oncologist (a blood cancer specialist, distinct from a general medical oncologist or surgical oncologist), whether the hospital insists on excisional lymph node biopsy with complete immunophenotyping for accurate subtyping, and whether PET-CT and bone marrow biopsy are available for staging. CION Cancer Clinics meets these criteria with 11 centres across Hyderabad and 1,000+ lymphoma cases managed every year.

Verify eight things in writing: a haemato-oncology-led team, tumour-board review with subtype-stratified planning, annual lymphoma case volume across subtypes, excisional lymph node biopsy with immunophenotyping and molecular testing, PET-CT and bone marrow biopsy infrastructure, NABH-accredited partners for biopsy and stem cell transplant and CAR-T pathway, insurance and ArogyaSri empanelment, and fertility preservation plus long-term survivorship monitoring.

Lymphoma is cancer that starts in the lymphatic system — the network of vessels and lymph nodes that's part of the immune system. It usually presents as swollen lymph nodes (in the neck, armpit, or groin), though it can affect other tissues. Leukaemia is cancer that starts in the bone marrow and primarily affects the blood, though some forms (like CLL) overlap with lymphomas. Both are blood cancers and treatment is primarily chemotherapy, but the diagnostic workup, subtyping, and protocols differ. The two main types of lymphoma are Hodgkin lymphoma (about 10% of cases, characterised by a specific cell type and generally very treatable) and non-Hodgkin lymphoma (about 90% of cases, an umbrella term covering more than 60 different subtypes ranging from slow-growing indolent lymphomas to fast-growing aggressive lymphomas).

Lymphoma outcomes are generally among the better outcomes in oncology, but vary enormously by type. Per US National Cancer Institute SEER data, 5-year relative survival for Hodgkin lymphoma is approximately 89% overall and exceeds 95% for early-stage disease. For non-Hodgkin lymphoma, overall 5-year survival is approximately 74%, but the range is huge: diffuse large B-cell lymphoma (the most common aggressive subtype) achieves cure in 60–70% of patients with R-CHOP chemoimmunotherapy; indolent lymphomas like follicular lymphoma typically run a much longer course with long-term survival measured in years to decades; aggressive subtypes like Burkitt lymphoma require intensive but often curative treatment. The hospital you choose directly affects whether you receive the correct subtype-specific protocol.

Costs vary by lymphoma subtype and treatment intensity. Indicative ranges: excisional lymph node biopsy ₹30,000–1 lakh; PET-CT ₹18,000–25,000; bone marrow biopsy ₹8,000–20,000; complete immunophenotyping and molecular testing ₹10,000–25,000; R-CHOP 6 cycles for aggressive B-cell NHL ₹2–5 lakh total; ABVD 6 cycles for Hodgkin lymphoma ₹1.5–3 lakh; rituximab per cycle ₹40,000–1 lakh; BTK inhibitor therapy ₹1–2 lakh per month; autologous stem cell transplant ₹15–25 lakh; allogeneic stem cell transplant ₹25–40 lakh; CAR-T cell therapy ₹50 lakh–1.5 crore. CION provides a written treatment plan and itemised cost estimate before treatment begins, with an EMI facility available on selected packages.

For lymphoma, the deciding factor is whether the hospital has a haemato-oncologist (a blood cancer specialist), a haemato-pathologist for accurate subtyping, and access to advanced therapies including stem cell transplant and CAR-T cell therapy for relapsed cases. A cancer-specialty hospital or network usually offers tighter haematology-oncology coordination, established subtyping pathways, day-care chemotherapy with experience in lymphoma-specific regimens, and partner pathways for transplant and CAR-T. A multi-specialty general hospital with a high-volume haematology unit can also work well. The structural fit for most patients is the cancer-specialty pathway with NABH-accredited transplant and CAR-T partners.

Lymphoma diagnosis is unusually dependent on the type of biopsy performed. The strongly preferred approach is excisional lymph node biopsy — surgical removal of an entire lymph node, which preserves the lymph node's internal architecture for pathological examination. Needle biopsies (core needle or fine needle aspiration) often provide insufficient tissue and break up the lymph node architecture, making accurate subtyping difficult. Because lymphoma has more than 60 distinct subtypes — each with different prognosis and treatment — getting the subtype right is essential, and that requires the pathologist seeing the lymph node intact along with complete immunophenotyping (testing for specific protein markers on the cells) and molecular testing. A hospital that takes lymphoma seriously will recommend excisional biopsy from the start rather than starting with a needle biopsy that needs to be repeated.

Watch-and-wait (also called active surveillance) is a legitimate evidence-based approach for some indolent (slow-growing) lymphomas — most commonly follicular lymphoma, but also some other low-grade subtypes — when the patient has no significant symptoms, no organ compromise, and a relatively low disease burden. Instead of starting chemotherapy immediately, the patient is closely monitored with regular clinical reviews and imaging. The reasoning is that indolent lymphomas can sometimes remain stable for years, and treatment carries side effects that are not justified when the disease isn't causing problems. When the disease eventually progresses or causes symptoms, treatment is started and is typically very effective. This approach is not a substitute for treating aggressive lymphomas — those need prompt chemotherapy. Watch-and-wait requires patient discipline (regular follow-up cannot be skipped) and is decided case-by-case at the tumour board.

Yes — CAR-T cell therapy is now available in India through select centres. CAR-T (chimeric antigen receptor T-cell therapy) is a modern, highly specialised treatment for certain B-cell lymphomas that have not responded to or have come back after standard chemotherapy. The patient's own immune cells are collected, modified in a laboratory to recognise and attack the lymphoma cells, and then given back to the patient. It is currently approved for relapsed or refractory diffuse large B-cell lymphoma and certain other B-cell lymphomas. CAR-T is expensive, requires specialised facilities, and is not the first treatment given for any lymphoma — but for patients who need it, it offers a chance of cure when other treatments have failed. CION coordinates CAR-T therapy through NABH-accredited partner centres with established CAR-T programmes.

Many qualified hospitals are empanelled for ArogyaSri and most major cashless insurers — but empanelment varies by centre and by procedure. Stem cell transplant, CAR-T cell therapy, and newer targeted drugs have specific scheme rules and may have caps. CION Cancer Clinics is empanelled for ArogyaSri and accepts most major cashless insurance providers and TPAs. Request a written cost estimate and confirm pre-authorisation before treatment begins, especially for stem cell transplant and CAR-T which can be substantial financial commitments.